| Pharmacokinetics/pharmacodynamics and the stages of drug development: role of modeling and simulation JY Chien, S Friedrich, MA Heathman, DP de Alwis, V Sinha The AAPS journal 7, E544-E559, 2005 | 204 | 2005 |
| Visualization: using computer graphics to explore data and present information JR Brown, R Earnshaw, M Jern, J Vince John Wiley & Sons, 1995 | 146 | 1995 |
| Pharmacokinetics of teriparatide (rhPTH [1–34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis J Satterwhite, M Heathman, PD Miller, F Marín, EV Glass, H Dobnig Calcified tissue international 87, 485-492, 2010 | 95 | 2010 |
| Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials JS Geiser, MA Heathman, X Cui, J Martin, C Loghin, JY Chien, ... Clinical pharmacokinetics 55, 625-634, 2016 | 82 | 2016 |
| Dose‐finding results in an adaptive, seamless, randomized trial of once‐weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD‐5) Z Skrivanek, BL Gaydos, JY Chien, MJ Geiger, MA Heathman, S Berry, ... Diabetes, Obesity and Metabolism 16 (8), 748-756, 2014 | 79 | 2014 |
| Effect of age on the pharmacokinetics of duloxetine in women MH Skinner, HY Kuan, A Skerjanec, ME Seger, M Heathman, L O'Brien, ... British journal of clinical pharmacology 57 (1), 54-61, 2004 | 78 | 2004 |
| Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation ED Lobo, T Quinlan, L O’Brien, MP Knadler, M Heathman Clinical pharmacokinetics 48, 189-197, 2009 | 54 | 2009 |
| Exposure-response analyses of ramucirumab from two randomized, phase III trials of second-line treatment for advanced gastric or gastroesophageal junction cancer J Tabernero, A Ohtsu, K Muro, E Van Cutsem, SC Oh, G Bodoky, ... Molecular cancer therapeutics 16 (10), 2215-2222, 2017 | 49 | 2017 |
| Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials ED Lobo, M Heathman, HY Kuan, S Reddy, L O’Brien, C Gonzales, ... Clinical pharmacokinetics 49, 311-321, 2010 | 47 | 2010 |
| Population pharmacokinetic meta‐analysis of ramucirumab in cancer patients L O'Brien, P Westwood, L Gao, M Heathman British journal of clinical pharmacology 83 (12), 2741-2751, 2017 | 33 | 2017 |
| Exposure-response (ER) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer. J Tabernero, A Ohtsu, K Muro, E Van Cutsem, SC Oh, G Bodoky, ... Journal of Clinical Oncology 33 (3_suppl), 121-121, 2015 | 28 | 2015 |
| Population pharmacokinetic modeling of olaratumab, an anti-PDGFRα human monoclonal antibody, in patients with advanced and/or metastatic cancer G Mo, JR Baldwin, D Luffer-Atlas, RL Ilaria, I Conti, M Heathman, ... Clinical pharmacokinetics 57, 355-365, 2018 | 23 | 2018 |
| Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator X Zhang, K Schneck, J Bue-Valleskey, KP Yeo, M Heathman, V Sinha Journal of pharmacokinetics and pharmacodynamics 40, 53-65, 2013 | 14 | 2013 |
| A population approach to enzyme characterization and identification: application to phenacetin O-deethylation DJ Belle, BJ Ring, SRB Allerheiligen, MA Heathman, LM O'Brien, V Sinha, ... Pharmaceutical research 17, 1531-1536, 2000 | 14 | 2000 |
| Exposure‐response modeling to characterize the relationship between ixekizumab serum drug concentrations and efficacy responses at week 12 in patients with moderate to severe … E Chigutsa, N Velez de Mendizabal, L Chua, M Heathman, S Friedrich, ... The Journal of Clinical Pharmacology 58 (11), 1489-1500, 2018 | 12 | 2018 |
| Interpretative neural networks for QSAR JH Wikel, ER Dow, M Heathman Network Science, 1583-0233, 1996 | 10 | 1996 |
| Population pharmacokinetic analysis of atomoxetine in pediatric patients J Witcher, D Kurtz, M Heathman, J Sauer, B Smith Clinical Pharmacology & Therapeutics 75 (2), P46-P46, 2004 | 8 | 2004 |
| Analytical applications of Raman spectroscopy in the pharmaceutical field LG Tensmeyer, MA Heathman TrAC Trends in Analytical Chemistry 8 (1), 19-24, 1989 | 8 | 1989 |
| Increases in serum-terminal propeptide of type I collagen with teriparatide treatment predict increases in lumbar spine bone density J Krege, M Heathman, J Reginster, J Satterwhite Program & Abstracts The Endocrine Society’s 85th Annual Meeting June, 19-22, 2003 | 7 | 2003 |
| Men and postmenopausal women with osteoporosis have similar lumbar spine bone mineral density responses to recombinant human parathyroid hormone (1-34) despite pharmacokinetic … J Satterwhite, K Melnick, L O'Brien, SL Myers, M Heathman Arthritis and Rheumatism 44 (9), S255-S255, 2001 | 6 | 2001 |
